Sezary Syndrome Clinical Trials

A listing of Sezary Syndrome medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
BI-1808 as a Single Agent and With Pembrolizumab in Treatment of Advanced Malignancies(Keynote-D20)

iRECIST can be applied for efficacy assessment) and subjects with cutaneous T-cell lymphoma (CTCL), specifically Sézary Syndrome (SS) and mycosis fungoides (MF). The study will consist of 2 phases

  • 38 views
  • 07 Oct, 2022
  • 5 locations
A Phase I Study With an Expansion Cohort of Duvelisib and Nivolumab in Mycosis Fungoides (MF) and Sezary Syndrome (SS)

Sezary syndrome. Duvelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's

  • 7 views
  • 24 Oct, 2022
  • 5 locations
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma. CTCL is a rare type of cancer that begins in the white blood cells called T cells. Erythrodermic is a widespread red …

microscopic examination
antibiotics
neutrophil count
sezary syndrome
extracorporeal photopheresis
  • 0 views
  • 07 Oct, 2022
  • 1 location
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors

This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in the body (advanced) or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, …

systemic therapy
neutrophil count
immunoglobulin
b-cell lymphomas
nivolumab
  • 511 views
  • 10 Oct, 2022
  • 6 locations
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

To learn if a form of radiation therapy (called ultra-low-dose - total skin electron beam therapy [ULD-TSEBT]) in combination with brentuximab vedotin can help to control mycosis fungoides

  • 0 views
  • 23 Oct, 2022
  • 1 location
Brentuximab Vedotin and BeEAM High-dose Chemotherapy (B-BeEAM) With Autologous Stem Cell Transplantation for CD30+ Lymphomas, a Phase I/II Study (BAL)

The trial assess the maximum tolerated dose of a single-dose of Brentuximab Vedotin added to standard BeEAM chemotherapy (comprising Bendamustin, Etoposide, Cyclophosphamide and Melphalan) before autologous stem cell transplantation in CD30+ malignant lymphomas.

remission
melphalan
solid tumor
high dose chemotherapy
neutrophil count
  • 4 views
  • 25 Oct, 2022
  • 1 location
Extracorporeal Photopheresis in Sezary Syndrome (ECP)

The primary endpoint is to determine if ECP induces a decrease in % of tumor cells after treatment. 15 patients with Sezary Syndrome will receive ECP weekly x4, then bi-weekly for 5 months. Each

white blood cells
ct scan
systemic therapy
sezary syndrome
extracorporeal photopheresis
  • 0 views
  • 04 Oct, 2022
  • 1 location
Mapping Emotional Dynamics During Corticosteroid Treatment

, which may help to overcome mood disturbances. Objective: Mapping emotional dynamics with DTW analysis in six mycosis fungoides or Sezary syndrome patients treated with systemic corticosteroids

  • 0 views
  • 07 Oct, 2022
  • 1 location